Table 1 Baseline characteristics
Prior Ipi only (n = 52) | No prior ICB (n = 276) | Total (n = 328) | |||||
|---|---|---|---|---|---|---|---|
Sex | Female | 20 | 38 % | 104 | 38 % | 124 | 38 % |
Male | 32 | 62 % | 172 | 62 % | 204 | 62 % | |
Age | <65 | 43 | 83 % | 234 | 85 % | 277 | 84 % |
≥65 | 9 | 17 % | 42 | 15 % | 51 | 16 % | |
Median | 52 | 53 | 53 | ||||
ECOG | 0 | 35 | 67 % | 190 | 69 % | 225 | 69 % |
1 | 15 | 29 % | 78 | 29 % | 98 | 28 % | |
2 | 0 | 3 | 1 % | 3 | 1 % | ||
Missing | 2 | 4 % | 5 | 1 % | 7 | 2 % | |
# of metastasis | 1 | 13 | 25 % | 82 | 30 % | 95 | 29 % |
2 | 20 | 38 % | 92 | 33 % | 112 | 34 % | |
≥3 | 17 | 33 % | 79 | 29 % | 96 | 29 % | |
Missing | 2 | 4 % | 23 | 8 % | 25 | 8 % | |
Prior treatments | Surgery | 42 | 81 % | 203 | 74 % | 245 | 75 % |
Radiation | 20 | 39 % | 84 | 31 % | 104 | 32 % | |
Chemotherapy | 11 | 21 % | 35 | 13 % | 16 | 5 % | |
Immunotherapy | 52 | 100 % | 85 | 31 % | 137 | 42 % | |
Targeted therapy | 9 | 17 % | 7 | 3 % | 46 | 14 % | |
Other | 2 | 4 % | 4 | 1 % | 6 | 2 % | |
No Prior Tx | 0 | 36 | 13 % | 36 | 11 % | ||
Melanoma Subtype | Cutaneous | 36 | 69 % | 195 | 71 % | 231 | 70 % |
Mucosal | 4 | 7 % | 15 | 5 % | 19 | 6 % | |
Ocular | 3 | 5 % | 6 | 2 % | 9 | 3 % | |
Acral | 1 | 2 % | 5 | 2 % | 6 | 2 % | |
Unknown | 8 | 15 % | 55 | 20 % | 63 | 19 % | |
BRAF statusa | WT | 20 | 56 % | 84 | 42 % | 104 | 45 % |
Mutated | 16 | 44 % | 114 | 57 % | 130 | 54 % | |
Not done | 0 | 2 | 1 % | 2 | 1 % | ||
NRASa | WT | 10 | 28 % | 64 | 32 % | 74 | 31 % |
Mutated | 6 | 17 % | 12 | 6 % | 18 | 8 % | |
Not done | 20 | 56 % | 124 | 62 % | 144 | 61 % | |
cKITa | WT | 16 | 44 % | 84 | 42 % | 103 | 43 % |
Mutated | 0 | 8 | 4 % | 8 | 4 % | ||
Not done | 20 | 56 % | 105 | 53 % | 125 | 53 % | |